Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
BMC Pulm Med ; 20(1): 83, 2020 Apr 03.
Article in English | MEDLINE | ID: mdl-32245452

ABSTRACT

BACKGROUND: Antipseudomonal antibiotics should be restricted to patients at risk of Pseudomonas aeruginosa infection. However, the indications in different guidelines on community-acquired pneumonia (CAP) are discordant. Our objectives were to assess the prevalence of antipseudomonal antibiotic prescriptions and to identify determinants of empirical antibiotic choices in the emergency department. METHODS: Observational, retrospective, one-year cohort study in hospitalized adults with pneumonia. Antibiotic choices and clinical and demographic data were recorded on a standardized form. Antibiotics with antipseudomonal activity were classified into two groups: a) ß-lactam antipseudomonals (ß-APS), including carbapenems, piperacillin / tazobactam or cefepime (in monotherapy or combination) and b) monotherapy with antipseudomonal quinolones. RESULTS: Data were recorded from 549 adults with pneumonia, with Pseudomonas aeruginosa being isolated in only nine (1.6%). Most (85%) prescriptions were compliant with SEPAR guidelines and 207 (37%) patients received antibiotics with antipseudomonal activity (14% ß-APS and 23% levofloxacin). The use of ß-APS was independently associated with ICU admission (OR 8.16 95% CI 3.69-18.06) and prior hospitalization (OR 6.76 95% CI 3.02-15.15), while levofloxacin was associated with negative pneumococcal urine antigen tests (OR 3.41 95% CI 1.70-6.85) but negatively associated with ICU admission (OR 0.26 95% CI 0.08-0.86). None of these factors were associated with P aeruginosa episodes. In univariate analysis, prior P aeruginosa infection/colonization (2/9 vs 6/372, p = 0.013), severe COPD (3/9 vs 26/372, p = 0.024), multilobar involvement (7/9 vs 119/372, p = 0.007) and prior antibiotic (6/9 vs 109/372, p = 0.025) were significantly associated with P aeruginosa episodes. CONCLUSIONS: Antipseudomonal prescriptions were common, in spite of the very low incidence of Pseudomonas aeruginosa. The rationale for prescription was influenced by both severity-of-illness and pneumococcal urine antigen test (levofloxacin) and prior hospitalization and ICU admission (ß-APS). However, these factors were not associated with P aeruginosa episodes. Only prior P aeruginosa infection/colonization and severe COPD seem to be reliable indicators in clinical practice.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Cross Infection/drug therapy , Emergency Service, Hospital , Prescriptions/statistics & numerical data , Pseudomonas Infections/drug therapy , Aged , Aged, 80 and over , Community-Acquired Infections/drug therapy , Female , Humans , Logistic Models , Male , Middle Aged , Multivariate Analysis , Pneumonia, Bacterial/drug therapy , Practice Guidelines as Topic , Pseudomonas aeruginosa/isolation & purification , Retrospective Studies , Spain
2.
Expert Rev Med Devices ; 2(1): 33-9, 2005 Jan.
Article in English | MEDLINE | ID: mdl-16293026

ABSTRACT

Sudden cardiac death is an unresolved problem which causes significant mortality and morbidity in both the community and in-hospital setting. Cardiac arrest is often caused by ventricular tachyarrhythmias which may be mostly interrupted by cardioversion or defibrillation. The single most critical factor for survival is the response time. Over the last 30 years, there have been virtually no procedural changes in the way hospitals address in-hospital resuscitation. A unique device has been developed that eliminates human intervention and assures defibrillation therapy is administered in seconds. This is accomplished with a fully automatic, external bedside monitor defibrillator designed to be prophylactically attached to hospitalized patients at risk of ventricular tachyarrhythmia. The safety and efficacy of the device has been demonstrated in multicenter US and European trials. Thus, this device allows a new scenario which may increase survival and enables meaningful redistribution of health resources.


Subject(s)
Defibrillators , Electric Countershock/instrumentation , Emergency Treatment/instrumentation , Heart Arrest/prevention & control , Hospitalization , Tachycardia, Ventricular/therapy , Therapy, Computer-Assisted/instrumentation , Clinical Trials as Topic , Critical Care/methods , Emergency Service, Hospital , Equipment Design , Equipment Failure Analysis , Europe , Heart Arrest/etiology , Humans , Tachycardia, Ventricular/complications , Technology Assessment, Biomedical , Therapy, Computer-Assisted/methods , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...